|
1
|
Shigematsu H, Lin L, Takahashi T, et al:
Clinical and biological features associated with epidermal growth
factor receptor gene mutations in lung cancers. J Natl Cancer Inst.
97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rodenhuis S, van de Wetering ML, Mooi WJ,
Evers SG, van Zandwijk N and Bos JL: Mutational activation of the
K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of
the lung. N Engl J Med. 317:929–935. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chan SK, Gullick WJ and Hill ME: Mutations
of the epidermal growth factor receptor in non-small cell lung
cancer - search and destroy. Eur J Cancer. 42:17–23. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ahrendt SA, Decker PA, Alawi EA, et al:
Cigarette smoking is strongly associated with mutation of the K-ras
gene in patients with primary adenocarcinoma of the lung. Cancer.
92:1525–1530. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paez JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pham D, Kris MG, Riely GJ, et al: Use of
cigarette-smoking history to estimate the likelihood of mutations
in epidermal growth factor receptor gene exons 19 and 21 in lung
adenocarcinomas. J Clin Oncol. 24:1700–1704. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sugio K, Uramoto H, Ono K, et al:
Mutations within the tyrosine kinase domain of EGFR gene
specifically occur in lung adenocarcinoma patients with a low
exposure of tobacco smoking. Br J Cancer. 94:896–903. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pao W, Wang TY, Riely GJ, et al: KRAS
mutations and primary resistance of lung adenocarcinomas to
gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bos JL: ras oncogenes in human cancer: a
review. Cancer Res. 49:4682–4689. 1989.PubMed/NCBI
|
|
11
|
Miller VA, Riely GJ, Zakowski MF, et al:
Molecular characteristics of bronchioloalveolar carcinoma and
adenocarcinoma, bronchioloalveolar carcinoma subtype, predict
response to erlotinib. J Clin Oncol. 26:1472–1478. 2008. View Article : Google Scholar
|
|
12
|
Nagai Y, Miyazawa H, Huqun, et al: Genetic
heterogeneity of the epidermal growth factor receptor in non-small
cell lung cancer cell lines revealed by a rapid and sensitive
detection system, the peptide nucleic acid-locked nucleic acid PCR
clamp. Cancer Res. 65:7276–7282. 2005. View Article : Google Scholar
|
|
13
|
Thiede C, Bayerdörffer E, Blasczyk R,
Wittig B and Neubauer A: Simple and sensitive detection of
mutations in the ras proto-oncogenes using PNA-mediated PCR
clamping. Nucleic Acids Res. 24:983–984. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Toh CK, Gao F, Lim WT, et al:
Never-smokers with lung cancer: epidemiologic evidence of a
distinct disease entity. J Clin Oncol. 24:2245–2251. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen YR, Fu YN, Lin CH, et al: Distinctive
activation patterns in constitutively active and
gefitinib-sensitive EGFR mutants. Oncogene. 25:1205–1215. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY
and Yang PC: Effectiveness of tyrosine kinase inhibitors on
‘uncommon’ epidermal growth factor receptor mutations of unknown
clinical significance in non-small cell lung cancer. Clin Cancer
Res. 17:3812–3821. 2011.
|
|
18
|
De Pas T, Toffalorio F, Manzotti M, et al:
Activity of epidermal growth factor receptor-tyrosine kinase
inhibitors in patients with non-small cell lung cancer harboring
rare epidermal growth factor receptor mutations. J Thorac Oncol.
6:1895–1901. 2011.
|
|
19
|
Bennett WP, Hussain SP, Vahakangas KH,
Khan MA, Shields PG and Harris CC: Molecular epidemiology of human
cancer risk: gene-environment interactions and p53 mutation
spectrum in human lung cancer. J Pathol. 187:8–18. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Le Calvez F, Mukeria A, Hunt JD, et al:
TP53 and KRAS mutation load and types in lung cancers in relation
to tobacco smoke: distinct patterns in never, former, and current
smokers. Cancer Res. 65:5076–5083. 2005.PubMed/NCBI
|
|
21
|
Riely GJ, Kris MG, Rosenbaum D, et al:
Frequency and distinctive spectrum of KRAS mutations in never
smokers with lung adenocarcinoma. Clin Cancer Res. 14:5731–5734.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Allegra CJ, Jessup JM, Somerfield MR, et
al: American Society of Clinical Oncology provisional clinical
opinion: testing for KRAS gene mutations in patients with
metastatic colorectal carcinoma to predict response to
anti-epidermal growth factor receptor monoclonal antibody therapy.
J Clin Oncol. 27:2091–2096. 2009. View Article : Google Scholar
|
|
23
|
O’Byrne KJ, Gatzemeier U, Bondarenko I, et
al: Molecular biomarkers in non-small-cell lung cancer: a
retrospective analysis of data from the phase 3 FLEX study. Lancet
Oncol. 12:795–805. 2011.PubMed/NCBI
|
|
24
|
Pirker R, Pereira JR, Szczesna A, et al:
Cetuximab plus chemotherapy in patients with advanced
non-small-cell lung cancer (FLEX): an open-label randomised phase
III trial. Lancet. 373:1525–1531. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mollerup S, Jorgensen K, Berge G and
Haugen A: Expression of estrogen receptors alpha and beta in human
lung tissue and cell lines. Lung Cancer. 37:153–159. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stabile LP, Davis AL, Gubish CT, et al:
Human non-small cell lung tumors and cells derived from normal lung
express both estrogen receptor alpha and beta and show biological
responses to estrogen. Cancer Res. 62:2141–2150. 2002.
|
|
27
|
Yu IT, Chiu YL, Au JS, Wong TW and Tang
JL: Dose-response relationship between cooking fumes exposures and
lung cancer among Chinese nonsmoking women. Cancer Res.
66:4961–4967. 2006. View Article : Google Scholar
|
|
28
|
Kleinerman RA, Wang Z, Wang L, et al: Lung
cancer and indoor exposure to coal and biomass in rural China. J
Occup Environ Med. 44:338–344. 2002. View Article : Google Scholar : PubMed/NCBI
|
